摘要
Updates in version 2.2019 of the NCCN guidelines for non-small cell lung cancer from version 1.2019 NSCL-22 ALK rearrangement positive metastatic NSCLC:Lorlatinib added as a treatment option after progression on crizotinib and alectinib,brigatinib,or ceritinib.NSCL-23 ALK rearrangement positive metastatic NSCLC:Lorlatinib added as a treatment option,after progression on alectinib,brigatinib,or ceritinib.NSCL-24 ROS1 rearrangement positive metastatic NSCLC:Lorlatinib added as a treatment option,after progression on crizotinib or ceritinib.
